Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma
Despite responses of chimeric antigen receptor (CAR)-T cells in patients with relapsed/refractory large B-cell lymphoma (LBCL), over half of patients eventually relapse. Methods to detect early disease persistence are needed to identify patients at high risk of treatment failure. We recently developed MAESTRO, an ultrasensitive, tumor-informed measurable residual disease (MRD) assay, which can detect parts-per-million (ppm) levels of circulating tumor DNA (ctDNA) using minimal sequencing. We applied MAESTRO to 140 samples from 28 patients (15 durable responders at 12 months and 13 nonresponders) to identify treatment failure after axicabtagene ciloleucel (axi-cel), administered at our institution between 2018 and 2022. Responder and nonresponder patients had similar baseline tumor burden. By 1 week after infusion, responders had marked ctDNA reduction compared to nonresponders (P < .001). At weeks 2 and 4, responders had ctDNA levels approaching 0 ppm, whereas nonresponders had persistence of ctDNA (each P < .001). At day 0, up to 21% of patients had ctDNA fractions <0.01%; hence, these individuals would not have qualified for ctDNA monitoring with a less sensitive test. Our results confirm the feasibility of highly sensitive MRD detection by ctDNA for early identification of patients at high risk of disease progression from axi-cel.
Authors
- Viktor A. Adalsteinsson (ORCID: https://orcid.org/0000-0003-4555-2485)
- Donna Neuberg (ORCID: https://orcid.org/0000-0003-2566-3145)
- Liliana Guerrero (ORCID: https://orcid.org/0009-0008-0183-0475)
- Brodie Miles (ORCID: https://orcid.org/0000-0002-5670-4432)
- Robert Allyn Redd (ORCID: https://orcid.org/0000-0002-1329-5288)
- Jacquelyn O. Wolff (ORCID: https://orcid.org/0000-0003-3257-9056)
- Mike Mattie (ORCID: https://orcid.org/0000-0003-0868-3865)
- Timothy Blewett
- Caron Alyce Jacobson (ORCID: https://orcid.org/0000-0002-0180-0654)
- Caitlyn Duffy (ORCID: https://orcid.org/0009-0003-3511-0250)
- Catherine J. Wu (ORCID: https://orcid.org/0000-0002-3348-5054)
- Katie Maurer (ORCID: https://orcid.org/0000-0002-4160-181X)
- Philippe A. Armand (ORCID: https://orcid.org/0000-0001-6098-1603)
- G. Mike Makrigiorgos (ORCID: https://orcid.org/0000-0001-7598-2406)
- Heather A. Jacene (ORCID: https://orcid.org/0000-0001-7167-078X)
- Scott J. Rodig (ORCID: https://orcid.org/0000-0003-1761-9769)
- Reid W. Merryman (ORCID: https://orcid.org/0000-0002-6360-3234)
- Lei Gao (ORCID: https://orcid.org/0000-0003-1476-1460)
- Nira A. Krasnow (ORCID: https://orcid.org/0000-0003-2487-8101)
- Justin Rhoades (ORCID: https://orcid.org/0000-0002-0630-908X)
- Kan Xiong
- Andjela Crnjac (ORCID: https://orcid.org/0009-0005-9651-4288)
- Satyen H. Gohil (ORCID: https://orcid.org/0000-0003-0484-991X)
- Catherine Song
- Jamie Dela Cruz
- Mikaela M. McDonough
Institutions
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- University College London Hospitals NHS Foundation Trust (GB)
- Harvard University (US)
- University of California, San Francisco (US)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (Australia) (AU)
- Kite (United States) (US)
- The London College (GB)
- University College London (GB)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- Blood Advances
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1182/bloodadvances.2024015788
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Leukemia and Lymphoma Society
- Gilead Sciences
- Dana-Farber Cancer Institute
- Gerstner Family Foundation
- Pharmacyclics